A recent US survey of diabetes specialists and academic generalists showed that specialists reported no major barriers to initiating insulin treatment in patients with type 2 diabetes, but the majority of academic generalists indicated several patient-derived barriers (e.g. patients’ fear of insulin) (7). The gene discussed is INS; the disease is type 2 diabetes mellitus.